Exome Asset Management LLC Portfolio Holdings

Exome Asset Management LLC

  • $133 Billion
  • Q4 2024

Exome Asset Management LLC has filed its 13F form on February 14, 2025 for Q4 2024 where it was disclosed a total value porftolio of $133 Billion distributed in 59 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Bridge Bio Pharma, Inc. with a value of $6.77B, Eli Lilly & CO with a value of $6.37B, Geron Corp with a value of $5.62B, Humana Inc with a value of $4.58B, and Guardant Health, Inc. with a value of $4.52B.

Examining the 13F form we can see an decrease of $14.8B in the current position value, from $148B to 133B.

Exome Asset Management LLC is based out at New York, NY

Below you can find more details about Exome Asset Management LLC portfolio as well as his latest detailed transactions.

Portfolio value $133 Billion
Healthcare: $114 Billion

Stock Holdings Table

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History
$4.96B
$6.77 Billion 5.09% of portfolio
246,700
Q4 2024 Added 16.92%
$869B
$6.37 Billion 4.78% of portfolio
8,247
Q4 2024 Reduced 21.06%
$608M
$5.62 Billion 4.22% of portfolio
1,561,152
Q4 2024 Added 72.48%
$32.3B
$4.58 Billion 3.44% of portfolio
18,066
Q4 2024 New
$4.41B
$4.52 Billion 3.39% of portfolio
147,800
Q4 2024 Added 64.59%
$451M
$4.46 Billion 3.35% of portfolio
1,083,487
Q4 2024 Added 161.31%
Disc Medicine Inc
-
$4.38 Billion 3.29% of portfolio
-
Q4 2024 Added 7.06%
$881M
$4.22 Billion 3.17% of portfolio
318,900
Q4 2024 New
$912M
$4.19 Billion 3.15% of portfolio
218,700
Q4 2024 New
Structure Therapeutics Inc
-
$4.12 Billion 3.1% of portfolio
-
Q4 2024 Added 26.46%
$205B
$3.88 Billion 2.91% of portfolio
7,427
Q3 2024 Added 16.81%
$2.89B
$3.81 Billion 2.86% of portfolio
119,467
Q4 2024 Added 19.03%
$122B
$3.69 Billion 2.77% of portfolio
65,200
Q4 2024 Reduced 16.41%
$145B
$3.62 Billion 2.72% of portfolio
40,500
Q4 2024 New
$15.6B
$3.55 Billion 2.67% of portfolio
22,450
Q3 2024 Added 20.38%
Soleno Therapeutics Inc
-
$3.47 Billion 2.61% of portfolio
-
Q4 2024 New
$3.31B
$3.19 Billion 2.39% of portfolio
40,580
Q4 2024 Added 103.46%
$4.41B
$3.1 Billion 2.33% of portfolio
65,883
Q4 2024 Added 12.46%
$5.46B
$2.77 Billion 2.08% of portfolio
31,800
Q4 2024 Reduced 13.35%
$138B
$2.74 Billion 2.06% of portfolio
29,700
Q4 2024 Reduced 40.6%
$3.66B
$2.33 Billion 1.75% of portfolio
130,412
Q4 2024 New
$1.5B
$2.31 Billion 1.73% of portfolio
137,716
Q4 2024 Reduced 0.32%
$1.62B
$2.18 Billion 1.63% of portfolio
81,473
Q4 2024 Added 36.02%
$4.51B
$2.15 Billion 1.61% of portfolio
61,367
Q4 2024 New
$282M
$2.15 Billion 1.61% of portfolio
699,698
Q4 2024 New
$1.36B
$2.15 Billion 1.61% of portfolio
40,123
Q4 2024 New
$11.1B
$2.14 Billion 1.61% of portfolio
9,000
Q4 2024 New
$721M
$2.01 Billion 1.51% of portfolio
159,552
Q4 2024 New
$2.21B
$1.91 Billion 1.43% of portfolio
68,608
Q4 2024 Reduced 11.01%
$2.17B
$1.86 Billion 1.39% of portfolio
117,500
Q4 2024 Added 223.69%
$23.5B
$1.85 Billion 1.39% of portfolio
10,000
Q4 2024 Reduced 34.64%
$447M
$1.76 Billion 1.32% of portfolio
225,323
Q4 2024 Reduced 25.04%
$1.13B
$1.56 Billion 1.17% of portfolio
28,178
Q4 2024 Reduced 38.21%
Karyopharm Therapeutics Inc
-
$1.56 Billion 1.17% of portfolio
-
Q3 2024 New
$152M
$1.36 Billion 1.02% of portfolio
103,504
Q4 2024 Reduced 30.81%
$173M
$1.33 Billion 1.0% of portfolio
283,599
Q4 2024 New
$326M
$1.25 Billion 0.94% of portfolio
113,096
Q4 2024 Reduced 35.96%
$6.12B
$1.22 Billion 0.92% of portfolio
37,600
Q4 2024 Reduced 20.0%
$2.85B
$1.19 Billion 0.9% of portfolio
90,100
Q3 2024 New
Tectonic Therapeutic Inc
-
$1.2 Billion 0.9% of portfolio
-
Q4 2024 Reduced 28.24%
Vyne Therapeutics Inc
-
$1.18 Billion 0.89% of portfolio
-
Q2 2024 Reduced 14.92%
$59.2M
$1.06 Billion 0.79% of portfolio
256,373
Q4 2024 New
Biohaven LTD
-
$1.05 Billion 0.79% of portfolio
-
Q4 2024 New
$122M
$993 Million 0.75% of portfolio
1,097,999
Q4 2024 Added 134.37%
$140M
$966 Million 0.73% of portfolio
389,333
Q4 2024 New
$124M
$743 Million 0.56% of portfolio
144,830
Q4 2024 New
$42.5M
$740 Million 0.56% of portfolio
1,117,600
Q4 2024 New
Acelyrin Inc
-
$736 Million 0.55% of portfolio
-
Q4 2024 New
$653M
$663 Million 0.5% of portfolio
54,738
Q4 2024 New

Summary

  • Portfolio
  • No. of Stocks 59
  • Current Value $133 Billion
  • Prior Value $148 Billion
  • Filing
  • Period Q4 2024
  • Filing Date February 14, 2025
  • Form Type 13F-HR
  • Activity in Q4 2024
  • New Purchases 23 stocks
  • Additional Purchases 12 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 17 stocks
Track This Portfolio

Track Exome Asset Management LLC Portfolio

Follow Exome Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exome Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Exome Asset Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email